Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Under Armour Inc Class A (UA) Price & Performance

Heron Therapeutics IncTrade
Under Armour Inc Class ATrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Under Armour Inc Class A — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Under Armour Inc Class A trades at $5.24 (market cap $2.48B). The key difference: Under Armour Inc Class A is far larger — about 39.1× Heron Therapeutics Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXUA
Market Cap
$63.41M$2.48B
Sector
HealthConsumer Cyclical
52-Week High
$1.49$7.88
52-Week Low
$0.32$3.96
Enterprise Value
$161.31M$3.46B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Under Armour Inc Class A

Under Armour (UA) trades at $5.925, down 5.2% with bearish technical signals. The company reported mixed Q2 2026 results with an earnings beat but faces revenue declines and negative profitability metrics. Recent news highlights lowered fiscal 2027 revenue outlook due to softer consumer demand in key markets. Cash flow remains negative with significant operational challenges.

The outlook remains challenging with declining revenue trends and negative margins. While analyst consensus shows mixed sentiment, the stock faces headwinds from competitive pressures and execution risks. Investment opportunity exists only for those betting on a successful turnaround despite current fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Under Armour Inc Class A

Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.

Read more on UA